GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer

Inclusion Criteria: 1. Age ≥18 years and ≤80 years; 2. ECOG physical condition score: 0\~1; 3. Histologically or cytologically confirmed malignant tumor of epithelial origin in the biliary system; 4. Preoperative imaging assessment of the disease stage was III/IV; 5. The main organs function well, and the examination indicators meet the following requirements: Routine blood tests: Hemoglobin ≥90 g/L (no blood transfusion within 14 days); Neutrophil count ≥1.5×10\^9/L; Platelet count ≥80×10\^9/L; Biochemical examination: Total bilirubin ≤2×ULN (upper normal value); ALT or AST ≤ 2.5×ULN; Endogenous creatinine clearance ≥ 50 mL /min (Cockcroft-Gault formula); 6. Sign the informed consent voluntarily; 9. Good compliance, and family members willing to cooperate with follow-up. Exclusion Criteria: 1. Patients with other uncured malignant tumors; 2. Pregnant or lactating women who are required to withdraw from the clinical trial if they become pregnant during the study period; 3. Previous antitumor therapy for the disease in this study; 4. Participated in clinical trials of other drugs within one month; 5. Patients with a known history of other systemic serious diseases before screening; 6. Long-term unhealed wounds or incomplete healing fractures; 7. Previous organ transplantation history; 8. Abnormal coagulation function; 9. Screening for overactivity/venous thrombosis events in the previous year, such as cerebrovascular accidents (including temporary ischemic attacks), deep vein thrombosis and pulmonary embolism; 10. Having a history of abuse of psychotropic substances and being unable to quit or having mental disorders; 11. A history of immune deficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; 12. Concomitant conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the patient's completion of the study.